Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
Biomarkers
Cognition
Motor subtype
Neurofilament light chain
PIGD
Parkinson’s disease
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
05 06 2020
05 06 2020
Historique:
received:
13
01
2020
accepted:
28
05
2020
entrez:
7
6
2020
pubmed:
7
6
2020
medline:
2
7
2021
Statut:
epublish
Résumé
The main motor subtypes of Parkinson's disease (PD) include tremor-dominant (TD) and postural instability gait disorder (PIGD), with varying disease course that warrant the development of biomarkers capable of predicting progression according to motor subtype. The PIGD subtype is associated with a poorer prognosis, hence identification of a biomarker associated with PIGD is clinically relevant. Neurofilament light (NfL) chain is a potential biomarker of disease severity in neurological disorders including PD. However, no study has investigated NfL and PD motor subtypes. Here, we aimed to investigate the diagnostic and prognostic utility of plasma NfL for PD motor subtypes in early Parkinson's disease. Given the higher risk for cognitive and motor decline in PIGD, we hypothesized that plasma NfL is a potential biomarker for PIGD. Plasma NfL was measured in 199 participants (149 PD and 50 healthy controls, HC) using an ultrasensitive single molecule array. Patients were classified into TD or PIGD based on MDS-UPDRS components. After 2 years, 115 patients were reassessed. Association between NfL and clinical measures in PIGD and TD at baseline and at 2-year follow-up were analysed. At baseline, plasma NfL levels were higher in PD than HC (8.8 ± 3.4 vs 16.2 ± 7.6 pg/ml, p < 0.0001), and differentiated PD from HC with a good diagnostic accuracy (AUC = 0.833, p < 0.001). At 2 years, NfL was higher in PIGD than TD (18.4 ± 14.5 vs 12.6 ± 4.4 pg/ml, p = 0.039). Within the PIGD group, higher NfL associated significantly with worse global cognition and UPDRS motor scores at baseline, and was able to predict motor and cognitive decline at a mean follow-up duration of 1.9 years, controlled for age, sex and disease duration. In this longitudinal study, we demonstrated for the first time the potential utility of plasma NfL as a diagnostic and prognostic biomarker in PIGD even at early stages of PD. These important novel findings will require further confirmation in larger, longitudinal PD cohorts.
Sections du résumé
BACKGROUND
The main motor subtypes of Parkinson's disease (PD) include tremor-dominant (TD) and postural instability gait disorder (PIGD), with varying disease course that warrant the development of biomarkers capable of predicting progression according to motor subtype. The PIGD subtype is associated with a poorer prognosis, hence identification of a biomarker associated with PIGD is clinically relevant. Neurofilament light (NfL) chain is a potential biomarker of disease severity in neurological disorders including PD. However, no study has investigated NfL and PD motor subtypes. Here, we aimed to investigate the diagnostic and prognostic utility of plasma NfL for PD motor subtypes in early Parkinson's disease. Given the higher risk for cognitive and motor decline in PIGD, we hypothesized that plasma NfL is a potential biomarker for PIGD.
METHODS
Plasma NfL was measured in 199 participants (149 PD and 50 healthy controls, HC) using an ultrasensitive single molecule array. Patients were classified into TD or PIGD based on MDS-UPDRS components. After 2 years, 115 patients were reassessed. Association between NfL and clinical measures in PIGD and TD at baseline and at 2-year follow-up were analysed.
RESULTS
At baseline, plasma NfL levels were higher in PD than HC (8.8 ± 3.4 vs 16.2 ± 7.6 pg/ml, p < 0.0001), and differentiated PD from HC with a good diagnostic accuracy (AUC = 0.833, p < 0.001). At 2 years, NfL was higher in PIGD than TD (18.4 ± 14.5 vs 12.6 ± 4.4 pg/ml, p = 0.039). Within the PIGD group, higher NfL associated significantly with worse global cognition and UPDRS motor scores at baseline, and was able to predict motor and cognitive decline at a mean follow-up duration of 1.9 years, controlled for age, sex and disease duration.
CONCLUSIONS
In this longitudinal study, we demonstrated for the first time the potential utility of plasma NfL as a diagnostic and prognostic biomarker in PIGD even at early stages of PD. These important novel findings will require further confirmation in larger, longitudinal PD cohorts.
Identifiants
pubmed: 32503574
doi: 10.1186/s13024-020-00385-5
pii: 10.1186/s13024-020-00385-5
pmc: PMC7275464
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Références
Parkinsonism Relat Disord. 2018 Nov;56:9-15
pubmed: 29934196
JAMA Neurol. 2019 Apr 1;76(4):470-479
pubmed: 30640364
JAMA Neurol. 2017 May 1;74(5):525-532
pubmed: 28264096
J Neural Transm (Vienna). 2017 Mar;124(3):353-360
pubmed: 27878377
Neurol Sci. 2018 Nov;39(11):1971-1976
pubmed: 30109466
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Neurology. 2017 May 9;88(19):1788-1794
pubmed: 28404801
Neurology. 2019 Mar 26;92(13):e1479-e1486
pubmed: 30814322
Mov Disord. 2020 Feb;35(2):288-295
pubmed: 31737952
Acta Neuropathol. 2016 Jun;131(6):935-49
pubmed: 27021906
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Mov Disord. 2019 Jun;34(6):876-883
pubmed: 30869825
Arch Neurol. 1999 Jan;56(1):33-9
pubmed: 9923759
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Neurology. 2019 Sep 10;93(11):e1104-e1111
pubmed: 31420461
Neurology. 2017 Mar 7;88(10):930-937
pubmed: 28179466
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
Parkinsonism Relat Disord. 2018 Oct;55:50-54
pubmed: 29779681
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
JAMA Neurol. 2013 Oct;70(10):1277-87
pubmed: 23979011
Cell Rep. 2016 Jun 14;15(11):2411-26
pubmed: 27264186
Ann Clin Transl Neurol. 2016 Feb 01;3(3):216-25
pubmed: 27042681
Neurology. 2016 Jun 14;86(24):2243-50
pubmed: 27178702
Neurology. 2017 Jun 13;88(24):2302-2309
pubmed: 28500227
Neurology. 2017 Nov 14;89(20):2108-2114
pubmed: 29046363
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Mov Disord. 2018 Feb;33(2):282-288
pubmed: 29205509